This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
Coptis chinensis works primarily through its high berberine content, which activates AMP-activated protein kinase (AMPK), a key enzyme regulating cellular energy metabolism. This mechanism helps improve insulin sensitivity and glucose uptake. Berberine also demonstrates antimicrobial activity by disrupting bacterial cell membranes and inhibiting pathogen enzyme function. Additionally, it modulates inflammatory pathways and supports cardiovascular health through lipid metabolism effects. Evidence Level: C (preclinical and limited clinical data).
Does Coptis chinensis interact with medications?
Yes, Coptis chinensis has significant drug interactions. It should not be combined with MAOI antidepressants due to potential hypertensive crisis. The berberine content may enhance effects of diabetes medications, increasing hypoglycemia risk. It may also interact with blood thinners, cytochrome P450 substrates, and blood pressure medications. Berberine can inhibit certain liver enzymes, potentially altering drug metabolism. Always consult a healthcare provider before combining with prescription medications. Evidence Level: C.
What is the recommended dosage for Coptis chinensis?
The typical adult dosage for Coptis chinensis is 2-5 grams of dried root prepared as a decoction daily. For standardized berberine extract, 500 mg taken three times daily is commonly used. Dosage may vary based on the specific condition being treated and individual tolerance. Always follow practitioner guidance, as the intensely bitter herb can cause gastric irritation at higher doses. Evidence Level: Traditional use with Level C clinical support.
Is Coptis chinensis safe during pregnancy?
No, Coptis chinensis is contraindicated during pregnancy and breastfeeding. The berberine content can cross the placental barrier and may stimulate uterine contractions, potentially causing miscarriage or premature labor. Neonatal jaundice has been associated with berberine exposure in newborns. Women of childbearing age should use effective contraception while taking Coptis chinensis supplements. This herb is rated unsafe for pregnant women. Evidence Level: C for safety data.
What is Coptis chinensis used to treat?
Coptis chinensis is traditionally used in Chinese medicine for treating digestive infections, bacterial diarrhea, and dysentery. Its antimicrobial properties make it effective against various gastrointestinal pathogens. Modern research suggests potential benefits for type 2 diabetes management through blood glucose regulation and cardiovascular health, including cholesterol reduction. It is also used to clear heat toxicity in traditional Chinese medicine frameworks. Evidence Level: C for clinical evidence; Traditional use for digestive applications.
PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Coptis chinensis (Chinese goldthread) is a traditional medicinal plant containing isoquinoline alkaloids, most notably berberine, used for its antimicrobial, anti-inflammatory, and metabolic regulatory properties [PMID:32335802, PMID:10767672].
Background
Coptis chinensis, also known as Huanglian in China, is a medicinal plant from the Ranunculaceae family [PMID:28533961, PMID:27774066]. Its dried rhizome is the primary part used in traditional medicine [PMID:27774066, PMID:10767672].
Traditional uses
It has been used for centuries in Traditional Chinese Medicine for clearing heat and detoxification [PMID:33181286, PMID:40234956]. Traditional applications include treating stomach inflammation, digestive tract ulcers, and cardiovascular-associated problems such as obesity and diabetes mellitus [PMID:33181286, PMID:27774066].
Active compounds
The herb contains isoquinoline alkaloids, including berberine (the primary constituent), epiberberine, coptisine, palmatine, jatrorrhizine, and magnoflorine [PMID:32335802, PMID:33152460, PMID:37637408]. It also contains bioactive proteins (approximately 25 kDa and 60 kDa), such as chitinase and $\beta$-glucosidase [PMID:42134700].
Mechanism of action
Coptis chinensis and its alkaloids act through multiple pathways: berberine regulates glycometabolism and lipid metabolism [PMID:32335802]; coptisine regulates NF-$\kappa$B, MAPK, PI3K/Akt, and NLRP3 inflammasome pathways [PMID:31622015]; and epiberberine utilizes Akt, ERK, and p53/Bax apoptosis pathways [PMID:33152460]. Additionally, it may modulate the microbiota-gut-brain axis and the TLR4/NF-$\kappa$B pathway [PMID:41131617, PMID:41197341].
Clinical evidence
Evidence BMetabolic Disorders (Lipid-lowering and Insulin Resistance)
Lipid-lowering and insulin-resistance improving actions have been clearly demonstrated in numerous randomized clinical trials [PMID:27671811].
Evidence CInfectious Diseases
Predominant clinical uses include bacterial diarrhea, intestinal parasite infections, and ocular trachoma infections [PMID:10767672].
Evidence DColorectal Cancer
Huang-Lian-Jie-Du Decoction (containing C. chinensis) may enhance the efficacy of Capecitabine-Oxaliplatin via Akkermansia muciniphila and CD8+ T cells [PMID:40972261].
Evidence DInflammatory Bowel Disease/Colitis
C. chinensis-derived extracellular vesicle-like nanoparticles (Cc-ELNs) alleviated colitis in mice by reducing neutrophil recruitment and inhibiting NETs [PMID:40517238].
Safety & adverse effects
Epiberberine is reported to have low toxicity [PMID:33152460]. In vitro studies showed that berberine can induce gene mutations in the Ames test and micronuclei in human lymphoblastoid cells by interfering with topoisomerase II; however, these effects were negated with metabolic activation and were not observed in primary human blood lymphocytes, suggesting a lack of relevance for human risk assessment [PMID:40354871].
Pregnancy & lactation
Experiments in pregnant rats and mice indicated that Chinese Goldthread Rhizome and berberine did not induce neonatal jaundice or affect glucose-6-phosphate dehydrogenase activity [PMID:19004212].
Evidence summary
Evidence ranges from high-level clinical trials for metabolic effects (Level B) to preliminary animal and in vitro studies for neuroprotective, anticancer, and anti-inflammatory effects (Level D).
PubMed sources
1.PMID: 32335802 (2020) — Biological properties and clinical applications of berberine. · Frontiers of medicine
2.PMID: 27671811 (2016) — Berberine and Its Role in Chronic Disease. · Advances in experimental medicine and biology
3.PMID: 40517238 (2025) — Coptis chinensis-derived extracellular vesicle-like nanoparticles delivered miRNA-5106 suppresses NETs by restoring zinc homeostasis to alleviate colitis. · Journal of nanobiotechnology
4.PMID: 10767672 (2000) — Berberine. · Alternative medicine review : a journal of clinical therapeutic
5.PMID: 39556986 (2024) — Huang-Lian-Jie-Du decoction alleviates cognitive impairment in high-fat diet-induced obese mice via Trem2/Dap12/Syk pathway. · Phytomedicine : international journal of phytotherapy and phytopharmacology
Government sources
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
6.PMID: 40117945 (2025) — Huang-Lian-Jie-Du decoction inhibits CD4+ T cell infiltration into CNS in MCAO rats by regulating BBB. · Phytomedicine : international journal of phytotherapy and phytopharmacology
8.PMID: 40234956 (2025) — Huang-Lian-Jie-Du decoction alleviates cognitive deficits in Alzheimer's disease model 5xFAD mice by inhibiting Trem2/Dap12 signaling pathway. · Chinese medicine
9.PMID: 40972261 (2025) — Huang-Lian-Jie-Du decoction enhances Capecitabine-Oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer. · Phytomedicine : international journal of phytotherapy and phytopharmacology
10.PMID: 40354871 (2025) — A weight of evidence approach to assess the human genotoxicity risk of Chinese goldthread botanical extract and its primary constituent berberine. · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
12.PMID: 35872445 (2022) — Anti-atopic dermatitis effect of a modified Huang-Lian-Jie-Du decoction and its active fraction on 2,4-dinitrobenzene and MC903-induced mouse models. · Phytomedicine : international journal of phytotherapy and phytopharmacology
13.PMID: 41197341 (2025) — Huang-Lian-Jie-Du decoction alleviates diabetic ischemic stroke by modulating gut microbiota-derived short-chain fatty acids. · Phytomedicine : international journal of phytotherapy and phytopharmacology
14.PMID: 28533961 (2017) — Transcriptome analyses provide insights into the difference of alkaloids biosynthesis in the Chinese goldthread (Coptis chinensis Franch.) from different biotopes. · PeerJ
15.PMID: 27774066 (2016) — Rhizoma Coptidis: A Potential Cardiovascular Protective Agent. · Frontiers in pharmacology
16.PMID: 31867052 (2019) — Huang-Lian Jie-Du decoction: a review on phytochemical, pharmacological and pharmacokinetic investigations. · Chinese medicine
17.PMID: 41131617 (2025) — Huang-Lian-Jie-Du decoction alleviates cognitive impairment in periodontitis rats through restoring microbiota-gut-brain axis and inhibiting neuroinflammation via TLR4/NF-κB pathway. · Chinese medicine
18.PMID: 42134700 (2026) — Physicochemical, structural, and functional characterization of key bioactive proteins from Coptis chinensis leaf and root. · International journal of biological macromolecules
19.PMID: 40154897 (2025) — Traditional Chinese medicine preparation Shuang-Huang-Lian in the treatment of influenza: A review. · Journal of ethnopharmacology
20.PMID: 39244173 (2025) — Huang-Lian-Jie-Du Decoction alleviates diabetic encephalopathy by regulating inflammation and pyroptosis via suppression of AGEs/RAGE/NF-κB pathways. · Journal of ethnopharmacology
21.PMID: 24716182 (2013) — The Anticancer Properties and Apoptosis-inducing Mechanisms of Cinnamaldehyde and the Herbal Prescription Huang-Lian-Jie-Du-Tang ( Huáng Lián Jiě Dú Tang) in Human Hepatoma Cells. · Journal of traditional and complementary medicine
22.PMID: 19004212 (2008) — A research on the erupted fetal diseases caused by traditional Chinese drugs--discussion from the issue that Chinese goldthread rhizome is prohibited in Singapore. · Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
23.PMID: 37637408 (2023) — Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms. · Frontiers in pharmacology
24.PMID: 40734903 (2025) — Coptis chinensis shows distinct effects on hyperlipidemia and gut microbiota in high-fat diet induced mice with cold or hot syndrome. · Chinese herbal medicines
25.PMID: 41962266 (2026) — The Scutellaria baicalensis-Coptis chinensis herb pair ameliorates ulcerative colitis via integrated modulation of the aryl hydrocarbon receptor/NLRP3 inflammasome axis with tryptophan metabolites. · Phytomedicine : international journal of phytotherapy and phytopharmacology
26.PMID: 36147356 (2022) — Cytokine storm-calming property of the isoquinoline alkaloids in Coptis chinensis Franch. · Frontiers in pharmacology
27.PMID: 35637516 (2022) — Metabolomics analyses of traditional Chinese medicine formula Shuang Huang Lian by UHPLC-QTOF-MS/MS. · Chinese medicine
28.PMID: 33181286 (2021) — Tracking evidences of Coptis chinensis for the treatment of inflammatory bowel disease from pharmacological, pharmacokinetic to clinical studies. · Journal of ethnopharmacology
29.PMID: 31622015 (2019) — Coptisine from Coptis chinensis exerts diverse beneficial properties: A concise review. · Journal of cellular and molecular medicine
30.PMID: 34332892 (2022) — Role of Coptis chinensis in antibiotic susceptibility of carbapenem-resistant Klebsiella pneumoniae. · Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi